Medical benefit pharmaceutical policies for providers
See the latest updates to our medical benefit pharmaceutical policies.
MBP 101.0 Zaltrap (ziv-aflibercept)
Zaltrap (ziv-aflibercept) acts as a soluble receptor that binds to human VEGF-A, to human VEGF-B), and to human PlGF. By binding to these endogenous ligands, ziv-aflibercept can inhibit the binding and activation of their cognate receptors. This inhibition can result in decreased neovascularization and decreased vascular permeability.
MBP 15.0 Zevalin (Ibritumomab tiuxetan (IDEC Y2B8))
ZevalinTM (ibritumomab tiuxetan) is the immunoconjugate resulting from a stable thiourea covalent bond between the monoclonal antibody ibritumomab and the linker-chelator tiuxetan. Zevalin binds specifically to the CD20 antigen (human B-lymphocyte-restricted differentiation antigen, Bp35) and prevents shedding from the cell surface and internalization upon antibody binding.
Learn more about Geisinger Health Plan.
Log in to NaviNet to access and view prior authorization information.
Clinical guidelines offer providers consistent and appropriate guidance for diagnosis and treatment of specific conditions or diseases.
Terms and conditions
View GHP’s terms and conditions.
Questions? Contact us
If you have questions or need more information, contact Geisinger Health Plan.